WO2017040786A1 - Multilayer genetic safety kill circuits based on single cas9 protein and multiple engineered grna in mammalian cells - Google Patents

Multilayer genetic safety kill circuits based on single cas9 protein and multiple engineered grna in mammalian cells Download PDF

Info

Publication number
WO2017040786A1
WO2017040786A1 PCT/US2016/049907 US2016049907W WO2017040786A1 WO 2017040786 A1 WO2017040786 A1 WO 2017040786A1 US 2016049907 W US2016049907 W US 2016049907W WO 2017040786 A1 WO2017040786 A1 WO 2017040786A1
Authority
WO
WIPO (PCT)
Prior art keywords
regulatory system
synthetic regulatory
cas9
grna
vpr
Prior art date
Application number
PCT/US2016/049907
Other languages
French (fr)
Inventor
Samira KIANI
Ron Weiss
Mohammad Reza EBRAHIMKHANI
Original Assignee
Massachusetts Institute Of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute Of Technology filed Critical Massachusetts Institute Of Technology
Priority to US15/755,623 priority Critical patent/US20180251789A1/en
Publication of WO2017040786A1 publication Critical patent/WO2017040786A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • C12N15/902Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22Ribonucleases RNAses, DNAses

Definitions

  • Cas9 is an RNA-guided DNA endonuclease that has been adopted for programmable genome editing and transcriptional regulation.
  • gRNA Cas9-associated guide RNA
  • the invention is a synthetic regulatory system comprising a multifunctional Cas nuclease and at least two distinct gRNAs, wherein the synthetic regulatory system modulates cleavage and transcription in a mammalian cell such as a human cell.
  • the system in some embodiments is a safety switch.
  • the two distinct gRNAs comprise a first gRNA of less than 15 nucleotides in length and a second gRNA of 15 or greater nucleotides in length.
  • the first gRNA has a length of 10-14 nucleotides.
  • the second gRNA has a length of 16-20 nucleotides.
  • a nucleic acid may encode the Cas nuclease and the at least two distinct gRNAs.
  • the Cas nuclease is fused to a transcriptional activation domain, such as VPR, or a transcriptional repression domain.
  • the synthetic regulatory system modulates cleavage and transcriptional activation in some embodiments. In other embodiments the synthetic regulatory system modulates cleavage and transcriptional repression. In yet other embodiments the synthetic regulatory system modulates cleavage, transcriptional repression and transcriptional activation.
  • a method for regulating a nucleic acid based therapeutic agent involves contacting a cell having a nucleic acid based therapeutic agent with a synthetic regulatory system comprising a multifunctional Cas nuclease and at least two distinct gRNAs, wherein the synthetic regulatory system modulates cleavage and transcription of the nucleic acid based therapeutic agent in the cell.
  • the nucleic acid based therapeutic agent may be a DNA based vaccine, a gene therapy or a chimeric antigen receptor T cell (CAR-T) in some embodiments.
  • the synthetic regulatory system modulates cleavage and transcription of the nucleic acid based therapeutic agent in the cell when exposed to an exogenous factor. In yet other embodiments the synthetic regulatory system modulates cleavage and transcription of the nucleic acid based therapeutic agent in the cell when exposed to a cellular factor.
  • FIGs. 1A-1D show design and experimental analysis in human cells with
  • IB is a schematic of parallel Cas9-VPR/14nt gRNA-based transcriptional repression and activation devices in a single cell.
  • a 14nt gRNA-a drives Cas9-VPR to a CRISPR-activatable promoter (CAP) and mediates the activation of tdTomato while another 14nt gRNA targets Cas9-VPR to a CRISPR repressible promoter (CRP) to repress EYFP expression.
  • CRISPR repressible promoter CRISPR repressible promoter
  • FIG. 1C shows schematics of a genetic kill switch designed to incorporate Cas9-VPR DNA cleavage and transcriptional activation functions.
  • a 14nt gRNA directs Cas9-VPR to a CAP to activate output EYFP expression.
  • Addition of doxycycline generates a 20nt gRNA that directs Cas9-VPR to the same region within the promoter, but cuts within the promoter, thereby decreasing EYFP output.
  • circuits containing dCas9-VPR instead, the same induction leads to enhanced activation. Shown are geometric mean and s.d. of means of EYFP for cells expressing >3xl0 MEFL of transfection marker EBFP.
  • FIG. ID illustrates a genetic kill circuit that incorporates all three functions of Cas9-VPR, DNA cleavage, transcriptional activation and repression.
  • Input gRNA that cuts within TALER coding sequences decreases available gRNA-a and reduces output expression. Shown are geometric mean and s.d. of means of EYFP for cells expressing >10 MEFL of transfection marker mKate.
  • FIGs. 2A-2D are simplified schematics of the circuits in FIG. 1.
  • FIG. 2A is a schematic of a Cas9-VPR and 14nt gRNA repression device.
  • FIG. 2B is a schematic of parallel Cas9-VPR/14nt gRNA-based transcriptional repression and activation devices in a single cell.
  • a 14nt gRNA-c drives Cas9-VPR to a CRISPR-activatable promoter (CAP) and mediates the activation of tdTomato while another 14nt gRNA targets Cas9-VPR to a CRISPR repressible promoter (CRP) to repress EYFP expression.
  • CAP CRISPR-activatable promoter
  • CRP CRISPR repressible promoter
  • FIG. 2C shows schematics of a genetic kill switch designed to incorporate Cas9-VPR DNA cleavage and transcriptional activation functions.
  • a 14nt gRNA directs Cas9-VPR to a CAP to activate output EYFP expression.
  • Addition of doxycycline generates a 20nt gRNA that directs Cas9-VPR to the same region within the promoter, but cuts within the promoter, thereby decreasing EYFP output.
  • FIG. 2D illustrates a genetic kill circuit that incorporates all three functions of Cas9- VPR: DNA cleavage, transcriptional activation, and repression.
  • Input gRNA cuts within TALER coding sequences, decreases available gRNA-a, and reduces output expression.
  • FIGs. 3A-3C show different promoter architectures used to analyze Cas9-VPR- medicated transcriptional repression.
  • FIG. 3A shows schematics of Cas9-VPR/14nt gRNA based transcriptional repression control unit.
  • FIG. 3B shows the architecture of different CRISPR Repressible Promoters (CRPs).
  • FIGs. 4A-4E show the analysis of the dynamics of a genetic kill switch circuit.
  • FIG. 4A is a schematic of a genetic kill switch designed such that 20nt and 14nt gRNAs compete for the same target site within a CAP (CRISPR-activatable promoter). Upon induction of 20nt gRNA and infrared fluorescent protein (iRFP) with doxycycline, reduction in EYFP expression is expected due to Cas9-VPR/20nt gRNA mediated cleavage within the CAP.
  • FIG. 4B shows that 14ntgRNA/Cas9-VPR mediated activation of EYFP is detectable around 24h post transfection and continues through 96h.
  • the control group received only the transfection marker EYFP and was measured 48h post transfection. Shown are geometric mean and s.d. of means of EYFP for cells expressing >2xl0 MEFL of transfection marker EBFP. Bars, left to right: Control, 24h, 48h, 72h, 96h.
  • FIG. 4C shows that, following addition of doxycycline, cells positive for iRFP and 20nt gRNA expression are detectable around 24h after transfection and remain high in iRFP expression until 96h. Shown are percent of cells expressing EBFP>10 7 MEFL and iRFP>10 6 5 relative to uninduced population. Each set of bars, left to right: 24h, 48h, 72h, 96h.
  • 4D shows the fraction of cells that have EYFP above autofluorescence relative to uninduced population in different treatment conditions and overtime. Shown are percent of cells expressing EBFP>10 MEFL and EYFP>10 5 5 relative to uninduced population.
  • the bars show the geometric mean ratio and standard deviation of mean ratio of uninduced vs. fully induced samples, for cells expressing > 10 MEFL of transfection marker EBFP.
  • Group 1 includes cells that received doxycycline (4000nM) at the time of transfection and group 2 includes cells that received doxycycline 24h after the transfection. A slower dynamic was observed in group 2, possibly due to initial accumulation of EYFP protein.
  • n 3 independent technical replicates combined from three experiments.
  • FIGs. 5A-5B provide insight into the design rules based on the concentrations of Cas9-VPR, 14nt gRNA, and 20nt gRNAs.
  • FIG. 5A is a schematic of a genetic kill switch designed such that 20nt and 14nt gRNAs compete for the same target site within a CAP.
  • FIG. 5B shows varying the dosages of transfected plasmids encoding Cas9-VPR, 14nt gRNA, 20nt-gRNA between low (5ng), medium (25ng for 14nt gRNA and 50ng for 20nt gRNA) and high (250ng) helps unravel some design rules.
  • Each line represents a single condition of transfection with corresponding Cas9, 14nt gRNA, and 20nt gRNA plasmid levels in front of the fold change observed upon addition of doxycycline.
  • Bar graphs show fold change of geometric mean and s.d. of means of EYFP over uninduced cells for cells expressing >3xl0 MEFL transfection marker EBFP.
  • n 3 independent technical replicates combined from three experiments.
  • FIGs. 6A-6B show the design and analysis of a genetic kill switch that functions based on DNA cleavage in the Cas9-VPR coding sequence.
  • FIGs. 7A-7B show the design and analysis of a genetic kill switch that operates based on DNA cleavage in TALER coding sequence and reversal of a transcriptional repression device.
  • FIG. 7A shows schematics of the kill switch involving a TALER-based
  • Tl-4 refer to 20nt gRNAs that cut at different regions in TALER coding sequence.
  • FIGs. 8A-8B show layering of the kill switch and cascade of the Cas9-VPR-mediated transcriptional repression devices.
  • FIG. 8A is a schematic of the layered kill switch.
  • CRISPR technology has been widely applied for genome editing and modulation.
  • the ease of engineering of the gRNA of the CRISPR system makes it an attractive platform for generating synthetic gene circuits and for synthetic biology purposes.
  • a multifunctional CRISPR system has been applied here to engineer genetic circuits (simple and multi-layer) that can be used for generating safety off and kill switches with lesser genetic materials than available in the prior art.
  • the technology of the invention involves the generation of circuits that can be packaged into delivery vehicles such as viruses that contain load limit for therapeutics, in a manner that could not be achieved using prior art methods.
  • the synthetic biology-based genetic circuits of the invention provide significant advantages that allow for custom designs that are capable of incorporating multiple inputs/signals from environments and cells, leading to the generation of a desired outcome (intended by current gene or cell-based therapies, referred to herein as nucleic acid based therapeutic agents) after and only after receiving and processing those inputs/signals.
  • Complex gene circuits have great utility because they allow better specificity and tighter controls for the desired therapeutic purposes such as safety switches. However, the more complex gene circuits become, the harder they become to engineer because of the metabolic load they create on cells.
  • a single Cas9 protein with multiple functionality (cleaving and transcriptional activation/ repression), such as that claimed herein, has great advantages because it provides better flexibility to engineer complex and multilayer genetic switches. These functionalities are achieved simply by altering and engineering gRNAs (which are small and easier to engineer).
  • Multi-layered and complex genetic off and kill switches in human cells using a Cas9 nuclease fused to a transcriptional activation domain (VPR), referred to as a multifunctional CRISPR was developed, as described in the examples below.
  • a Cas nuclease is part of a CRISPR system.
  • the components of the synthetic regulatory system of the invention may be in the form of one or more polynucleotide sequences.
  • one or more polynucleotides may have sequences which encode a Cas nuclease, the at least 2 gRNAs (guide RNAs) and optionally a tracr sequence. When transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence- specific binding of a CRISPR complex to the target sequence.
  • the polynucleotide sequence may be DNA or RNA or hybrids thereof.
  • a CRISPR enzyme is typically a type I or III CRISPR enzyme, preferably a type II CRISPR enzyme.
  • the type II CRISPR enzyme may be any Cas enzyme.
  • a preferred Cas enzyme is a Cas9 enzyme.
  • the Cas9 enzyme may be from a spCas9 or saCas9 or may have a high degree of sequence homology with, a wildtype enzyme.
  • the Cas enzyme can be any naturally-occurring Cas9 as well as any chimaeras, mutants, homologs or orthologs.
  • the polynucleotides may be under the control of a promoter, such as an inducible promoter.
  • a promoter such as an inducible promoter.
  • Inducible promoters allow regulation of gene expression and can be regulated by exogenously supplied compounds, environmental factors such as temperature, or the presence of a specific physiological state, e.g., acute phase, a particular differentiation state of the cell, or in replicating cells only.
  • Inducible promoters and inducible systems are available from a variety of commercial sources, including, without limitation, Invitrogen, Clontech and Ariad. Many other systems have been described and can be readily selected by one of skill in the art.
  • inducible promoters regulated by exogenously supplied promoters include the zinc-inducible sheep metallothionine (MT) promoter, the dexamethasone (Dex) -inducible mouse mammary tumor virus (MMTV) promoter, the T7 polymerase promoter system [WO 98/10088]; the ecdysone insect promoter [No et al, Proc. Natl. Acad. Sci. USA, 93:3346- 3351 (1996)], the tetracycline-repressible system [Gossen et al, Proc. Natl. Acad. Sci.
  • MT zinc-inducible sheep metallothionine
  • Dex dexamethasone
  • MMTV mouse mammary tumor virus
  • T7 polymerase promoter system [WO 98/10088]
  • ecdysone insect promoter No et al, Proc. Natl. Acad. Sci. USA, 93:3346- 3351 (
  • inducible promoters which may be useful in this context are those which are regulated by a specific physiological state, e.g., temperature, acute phase, a particular differentiation state of the cell, or in replicating cells only.
  • the system of the invention may be used as a safety switch. For instance it may be used to control the expression and activity of intracellular nucleic acid target DNA in highly regulatable and precise manner.
  • the target nucleic acid may be a nucleic acid or cellular therapy.
  • the system of the invention can be designed to target DNA sequences of these therapeutics in order to reverse or shut down the effects of such therapeutics.
  • the target DNA may be disrupted in its entirety in response to the methods of the invention. In some instances at least about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% of the target DNA is disrupted by use of the systems described herein. In some embodiments, at least about 60%, 70%, or 80% by of the target DNA is disrupted by administration of the systems of the invention. In some embodiments, at least about 85%, 90%, or 95% or more of the target DNA is disrupted.
  • the systems are useful for disrupting or interfering with the activity of therapeutics such as gene therapy, plasmid or viral vectors, cell based therapies such as CAR-Ts.
  • therapeutics such as gene therapy, plasmid or viral vectors, cell based therapies such as CAR-Ts.
  • each of these therapies may be selectively turned off, for instance when the therapy is complete or if the subject has an adverse reaction to the therapy.
  • Other uses are evident to the skilled artisan.
  • Example 1 Cas9 gRNA engineering for selectable genome editing, activation, and repression
  • Cas9 is directed to a specific DNA sequence by a short guide RNA (gRNA) that contains 20 nucleotides (nt) complementary to its target.
  • gRNA short guide RNA
  • gRNAs containing ⁇ 16nt showed a drastic reduction in nuclease activity.
  • CRISPR-repressible promoters 9 was first developed in order to identify promoter architectures that allow efficient Cas9-VPR mediated transcriptional repression (FIGs. 2A, 3).
  • CRP-8 high-performance member of this promoter library
  • CRP-a similar repression efficiency ( ⁇ 10-fold) was confirmed using dCas9 or Cas9-VPR with a 14nt gRNA to this promoter (FIG. 1A).
  • Cas9-VPR and 14nt gRNAs in a single cell to achieve simultaneous transcriptional activation and repression was then evaluated.
  • a CRP was placed upstream of Enhanced Yellow Protein (EYFP) and a CRISPR-activatable promoter (CAP) was placed upstream of tdTomato fluorescent protein, and were transfected into HEK293FT cells with other circuit regulatory elements.
  • EYFP Enhanced Yellow Protein
  • CAP CRISPR-activatable promoter
  • Flow cytometry analysis 48h post transfection showed simultaneous repression and activation of fluorescent reporters ( ⁇ 15-fold) were achieved with two 14nt gRNAs that target Cas9-VPR to the two promoters (FIGs. IB, 2B).
  • a genetic kill switch in which a 20nt gRNA that cuts within a CAP, is expressed under a tetracycline response element (TRE) promoter was designed 9 ' 10 .
  • TRE tetracycline response element
  • Cas9-VPR in combination with constitutively expressed 14nt gRNA for the same target within the CAP activates expression of EYFP.
  • the 20nt guide enables Cas9-VPR to bind and cut within the CAP, leading to reduction of EYFP expression (FIGs. 1C, 2C).
  • a genetic kill switch design that operates by modulating the availability of Cas9-VPR within a cell was then tested.
  • the guides directed Cas9- VPR to cut and disable itself and by doing so, decreased the available pool of Cas9-VPR within the cell, ultimately causing reduction of Cas9-VPR andl4nt gRNAs mediated inhibition or activation of the two fluorescent reporters (FIG. 14).
  • TALER 11 ' 12 was employed, and whether Cas9-VPR could cleave within the TALER coding sequence and decrease available TALER, thus removing its repression of EYFP was examined (FIG. 7).
  • a modified U6 promoter 9 regulated by TALER was generated, which enabled one to connect the above genetic kill switch with a Cas9-VPR 14nt gRNA repression device. Transfection of this circuit in HEK293FT cells exhibited repression of output EYFP upon addition of input 20nt gRNAs that cut within the TALER coding sequence (FIG. 8).
  • FIG. 8 the genetic kill switch described in FIG.
  • FIG. 8 was combined and interconnected with a Cas9-VPR-mediated transcriptional activation device to build a multilayered genetic circuit that simultaneously incorporates CRISPR-mediated transcriptional repression, activation, and DNA cleavage in a single circuit to modulate the output (FIGs. ID, 2D).
  • Flow cytometry analysis 24 and 48 h after transfection of HEK293FT revealed a functional circuit regulated by the input 20nt gRNA against TALER (FIG. ID).
  • Fluorescent reporter experiments for FIGs. 3-4 were conducted with a plasmid (Addgene #47320) modified to include an extra gRNA binding site lOObp upstream of the already existing one.
  • a plasmid (Addgene #47320) modified to include an extra gRNA binding site lOObp upstream of the already existing one.
  • the protospacer remained the same but the PAM sequence was modified as needed for ST1 or SA Cas9.
  • FIG. 6 all experiments were conducted with a reporter with a single gRNA binding site.
  • Reporter 1 denotes Addgene #47320
  • reporters 2 and 3 are similar to reporter 1 except the protospacer and PAM (in bold) were changed to contain the sequence
  • AAGAGAGACAGTACATGCCCTGG (SEQ ID NO: 2) respectively.
  • gRNAs of various length were co-transfected along with the indicated Cas9 protein and reporter into HEK293T cells along with an EBFP2 transfection control. Cells were analyzed by flow cytometry 48 hours post transfection and then when necessary were lysed to extract genomic DNA. Reporter Deletion Analysis
  • cDNA was made using the iScript cDNA synthesis kit (Bio-Rad) with 500ng of RNA.
  • KAPA SYBR FAST Universal 2X qPCR Master Mix (Kapa Biosystems) was used for qPCR with 0.5 ⁇ of cDNA used for each reaction.
  • Activation was analyzed using CFX96 Real-Time PCR Detection System (Bio-Rad). Gene expression levels were normalized to ⁇ - actin levels. Endogenous Indel Analysis
  • Mate pair reads were merged into single contigs using FLASH 18. Each contig was then mapped to a custom reference representing the three amplicons using bwa mem 19 .
  • SAM output files were then converted to BAM files and pileup files were generated for each sample using SAM tools 20. Pileup files were then analyzed using custom python scripts to determine observed mutation rates. Mutations were only counted if the mutations spanned some portion of the sgRNA target site. In addition, base quality scores of > 28 were also required for any mutations to be called. To minimize the impact of sequencing error, single base substitutions were excluded in this analysis.
  • RNA was polyA selected using Dynabeads mRNA Purification Kit (Life Technologies). The RNA was then DNAse treated with Turbo DNase (Life Technologies) and cleaned up with Agencourt RNAClean XP Beads (Beckman
  • RNA-Seq Libraries were made using the NEBNext Ultra RNA Library Prep Kit for Illumina (New England BioLabs) according to the manufacturer's instructions with NEBNext Multiplex Oligos (New England BioLabs). Libraries were analyzed on a BioAnalyzer using a High Sensitivity DNA Analysis Kit (Agilent). Libraries were then quantified using a
  • HEK-293T cells were cultivated in Dulbecco's Modified Eagle Medium (Life Technologies) with 10% FBS (Life Technologies) and Penicillin/Streptomycin (Life Technologies).
  • HEK293FT cells were obtained from ATCC or were a gift from P. Mali , maintained in DMEM (CellGro) supplemented with 10% FBS (PAA Laboratories), 1% 1-glutamine-streptomycin- penicillin mix (CellGro) and 1% nonessential amino acids (NEAA; HyClone) at 37 °C and 5% C0 2 and tested for mycoplasma contamination. Transfections were performed using lipofectamine LTX and Attractene reagents (QIAGEN). Cells were seeded the day before transfection at 2 x 10 5 cells per well in a 24-well plate.
  • the DNA plasmid under study was replaced with an equivalent amount of empty DNA plasmid to maintain the total amount of transfected DNA constant among the groups.
  • Attractene reagent cocktails of plasmid DNAs were mixed and added to serum free DMEM to a total volume of 70 ⁇ 1. 1.5- 2 ⁇ 1 of Attractene was then added to each tube of DNA/DMEM mixtures, and the tube was gently mixed and kept at room temperature for 25 min to form the DNA-liposome complex.
  • cocktails of plasmid DNAs, serum- free DMEM and the Plus Reagent were mixed and incubated for lOmin.
  • LTX reagent was mixed with the serum-free media and incubated for the same period of time. After 10 min, the two reagents were mixed and incubated for an additional 30 min. Fresh medium was added to the cells directly before transfection (500 ml of DMEM with supplements). The DNA-reagent solution was then added drop- wise to the wells. Induction of the circuit was performed at this time as well by addition of doxycycline.
  • Cas9- VPR was cloned via Gateway assembly (Invitrogen) based on the Cas9 plasmid. gRNAs for endogenous targets were cloned into Addgene #41817 and transiently transfected. Plasmids used for synthetic circuits were constructed using the Gateway system. The U6-driven gRNA expression cassettes were ordered as blocks from IDT and cloned into a plasmid backbone using Golden Gate cloning.
  • Flow cytometry data were collected 48 h after transfection. Cells were trypsinized and centrifuged at 453g for 5 min at 4 °C. The supernatant was then removed, and the cells were resuspended in Hank's balanced salt solution without calcium or magnesium supplemented with 2.5% FBS.
  • BD LSRII was used to obtain flow cytometry measurements with the following settings: EBFP, measured with a 405 nm laser and a 450/50 filter; EYFP, measured with a 488 nm laser and a 530/30 filter; tdTomato, measured with a 561 nm laser and a 695/40 filter. Non-transfected controls were included in each experiment.
  • Flow cytometry data were converted from arbitrary units to compensated molecules of equivalent fluorescein (MEFL) 24 using the Tool-Chain to Accelerate Synthetic Biological Engineering (TASBE) characterization 25 (MIT CSAIL Tech. Report 2012-008 (2012).
  • An affine compensation matrix is computed from single positive and blank controls.
  • FITC measurements are calibrated to MEFL using SpheroTech RCP-30-5-A beads, and mappings from other channels to equivalent FITC are computed from co-transfection of constitutive blue, yellow and red fluorescent proteins, each controlled by the CAG promoter on its own otherwise identical plasmid. Non-transfected controls were included in each experiment. Sample sizes were pre-determined for each experiment. Data shown in the figures are geometric mean and s.d.

Abstract

Aspects of the disclosure relate to synthetic regulatory systems composed of a multifunctional Cas [clustered regularly interspaced short palindromic repeat (CRISPR)-associated (Cas)] nuclease and at least two distinct guide RNAs (gRNAs). The synthetic regulatory system modulates cleavage and transcription, including repression and activation, in a mammalian cell such as a human cell.

Description

MULTILAYER GENETIC SAFETY KILL CIRCUITS BASED ON SINGLE CAS9 PROTEIN AND MULTIPLE ENGINEERED gRNA IN MAMMALIAN CELLS
RELATED APPLICATION
This application claims the benefit under 35 U.S.C. § 119(e) of U.S. provisional application number 62/214,839, filed September 4, 2015, which is incorporated by reference herein in its entirety.
BACKGROUND OF INVENTION
Since its adaptation for site-specific DNA cleavage in 2012, the CRISPR-Cas9 system from Streptococcus pyogenes (SP-Cas9) has been widely used for genome editing in a variety of organisms, from prokaryotes to eukaryotes 1 ' 2. By mutating residues involved in DNA catalysis, researchers have generated nuclease-null (dCas9) variants that retain the ability to bind DNA but lack endonucleolytic activity . These dCas9 variants were later functionalized with effector domains such as transcriptional activation domains (ADs) or repression domains (RDs), enabling Cas9 to serve as a tool for programming transcriptional activity 4-"7.
SUMMARY OF INVENTION
Cas9 is an RNA-guided DNA endonuclease that has been adopted for programmable genome editing and transcriptional regulation. Currently, no method exists to readily switch Cas9 between nuclease competent and nuclease null states. It has been demonstrated according to the invention that, by altering the length of the Cas9-associated guide RNA (gRNA), Cas9 nuclease activity can be controlled, enabling the simultaneous performance of genome editing and transcriptional activation or repression with a single Cas9 protein. These principles were exploited to engineer several mammalian synthetic circuits with combined transcriptional regulation and kill functions all governed by a single multifunctional Cas9 protein.
In some aspects, the invention is a synthetic regulatory system comprising a multifunctional Cas nuclease and at least two distinct gRNAs, wherein the synthetic regulatory system modulates cleavage and transcription in a mammalian cell such as a human cell. The system in some embodiments is a safety switch. In some embodiments the two distinct gRNAs comprise a first gRNA of less than 15 nucleotides in length and a second gRNA of 15 or greater nucleotides in length. In other embodiments the first gRNA has a length of 10-14 nucleotides. In yet other embodiments the second gRNA has a length of 16-20 nucleotides.
A nucleic acid may encode the Cas nuclease and the at least two distinct gRNAs.
In some embodiments the Cas nuclease is fused to a transcriptional activation domain, such as VPR, or a transcriptional repression domain.
The synthetic regulatory system modulates cleavage and transcriptional activation in some embodiments. In other embodiments the synthetic regulatory system modulates cleavage and transcriptional repression. In yet other embodiments the synthetic regulatory system modulates cleavage, transcriptional repression and transcriptional activation.
A method for regulating a nucleic acid based therapeutic agent is also provided according to aspects of the invention. The method involves contacting a cell having a nucleic acid based therapeutic agent with a synthetic regulatory system comprising a multifunctional Cas nuclease and at least two distinct gRNAs, wherein the synthetic regulatory system modulates cleavage and transcription of the nucleic acid based therapeutic agent in the cell. The nucleic acid based therapeutic agent may be a DNA based vaccine, a gene therapy or a chimeric antigen receptor T cell (CAR-T) in some embodiments.
In other embodiments the synthetic regulatory system modulates cleavage and transcription of the nucleic acid based therapeutic agent in the cell when exposed to an exogenous factor. In yet other embodiments the synthetic regulatory system modulates cleavage and transcription of the nucleic acid based therapeutic agent in the cell when exposed to a cellular factor.
Each of the limitations of the invention can encompass various embodiments of the invention. It is, therefore, anticipated that each of the limitations of the invention involving any one element or combinations of elements can be included in each aspect of the invention. This invention is not limited in its application to the details of construction and the arrangement of components set forth in the following description or illustrated in the drawings. The invention is capable of other embodiments and of being practiced or of being carried out in various ways. Also, the phraseology and terminology used herein is for the purpose of description and should not be regarded as limiting. The use of "including," "comprising," or "having," "containing," "involving," and variations thereof herein, is meant to encompass the items listed thereafter and equivalents thereof as well as additional items.
These and other aspects of the invention, as well as various embodiments thereof, will become more apparent in reference to the drawings and detailed description of the invention.
BRIEF DESCRIPTION OF DRAWINGS
The accompanying drawings are not intended to be drawn to scale. In the drawings, each identical or nearly identical component that is illustrated in various figures is represented by a like numeral. For purposes of clarity, not every component may be labeled in every drawing. In the drawings:
FIGs. 1A-1D show design and experimental analysis in human cells with
multifunctional CRISPR devices and circuits. FIG. 1A is a schematic of a Cas9-VPR and 14nt gRNA repression device (top). EYFP output fluorescence was measured for samples transfected with or without 14nt gRNA vector and comparison was made with a dCas9/14nt gRNA-based repression device. Shown are geometric mean and s.d. of means of EYFP for cells expressing >10 Molecules of Equivalent Fluorescein (MEFL) of transfection marker EBFP. n = 3 independent technical replicates combined from three experiments (n = 2 for +Cas9-VPR + gRNA). FIG. IB is a schematic of parallel Cas9-VPR/14nt gRNA-based transcriptional repression and activation devices in a single cell. A 14nt gRNA-a drives Cas9-VPR to a CRISPR-activatable promoter (CAP) and mediates the activation of tdTomato while another 14nt gRNA targets Cas9-VPR to a CRISPR repressible promoter (CRP) to repress EYFP expression. Shown are geometric mean and s.d. of means of EYFP for cells expressing >10 MEFL of transfection marker EBFP. n = 4 independent technical replicates combined from three experiments. FIG. 1C shows schematics of a genetic kill switch designed to incorporate Cas9-VPR DNA cleavage and transcriptional activation functions. A 14nt gRNA directs Cas9-VPR to a CAP to activate output EYFP expression. Addition of doxycycline generates a 20nt gRNA that directs Cas9-VPR to the same region within the promoter, but cuts within the promoter, thereby decreasing EYFP output. In circuits containing dCas9-VPR instead, the same induction leads to enhanced activation. Shown are geometric mean and s.d. of means of EYFP for cells expressing >3xl0 MEFL of transfection marker EBFP. n = 3 independent technical replicates combined from three experiments (n = 2 for Cas9-VPR-dox). Left two bars: Cas9-VPR. Right two bars: dCas9-VPR. FIG. ID illustrates a genetic kill circuit that incorporates all three functions of Cas9-VPR, DNA cleavage, transcriptional activation and repression. Input gRNA that cuts within TALER coding sequences decreases available gRNA-a and reduces output expression. Shown are geometric mean and s.d. of means of EYFP for cells expressing >10 MEFL of transfection marker mKate. n = 4 independent technical replicates combined from three experiments (n = 2 in 48h groups).
FIGs. 2A-2D are simplified schematics of the circuits in FIG. 1. FIG. 2A is a schematic of a Cas9-VPR and 14nt gRNA repression device. FIG. 2B is a schematic of parallel Cas9-VPR/14nt gRNA-based transcriptional repression and activation devices in a single cell. A 14nt gRNA-c drives Cas9-VPR to a CRISPR-activatable promoter (CAP) and mediates the activation of tdTomato while another 14nt gRNA targets Cas9-VPR to a CRISPR repressible promoter (CRP) to repress EYFP expression. FIG. 2C shows schematics of a genetic kill switch designed to incorporate Cas9-VPR DNA cleavage and transcriptional activation functions. A 14nt gRNA directs Cas9-VPR to a CAP to activate output EYFP expression. Addition of doxycycline generates a 20nt gRNA that directs Cas9-VPR to the same region within the promoter, but cuts within the promoter, thereby decreasing EYFP output. FIG. 2D illustrates a genetic kill circuit that incorporates all three functions of Cas9- VPR: DNA cleavage, transcriptional activation, and repression. Input gRNA cuts within TALER coding sequences, decreases available gRNA-a, and reduces output expression.
FIGs. 3A-3C show different promoter architectures used to analyze Cas9-VPR- medicated transcriptional repression. FIG. 3A shows schematics of Cas9-VPR/14nt gRNA based transcriptional repression control unit. FIG. 3B shows the architecture of different CRISPR Repressible Promoters (CRPs). FIG. 3C show the geometric mean and s.d. of means of EYFP for cells expressing >10 MEFL of transfection marker EBFP (n=3 technical replicates). The highest repression was achieved using CRP-8. Some of the promoters designed for repression purposes unexpectedly led to activation, which require further analysis to understand the effect of spacing between Cas9-VPR target sites at the promoters or location of targeting (downstream of the promoter) on this observation.
FIGs. 4A-4E show the analysis of the dynamics of a genetic kill switch circuit. FIG. 4A is a schematic of a genetic kill switch designed such that 20nt and 14nt gRNAs compete for the same target site within a CAP (CRISPR-activatable promoter). Upon induction of 20nt gRNA and infrared fluorescent protein (iRFP) with doxycycline, reduction in EYFP expression is expected due to Cas9-VPR/20nt gRNA mediated cleavage within the CAP. FIG. 4B shows that 14ntgRNA/Cas9-VPR mediated activation of EYFP is detectable around 24h post transfection and continues through 96h. The control group received only the transfection marker EYFP and was measured 48h post transfection. Shown are geometric mean and s.d. of means of EYFP for cells expressing >2xl0 MEFL of transfection marker EBFP. Bars, left to right: Control, 24h, 48h, 72h, 96h. FIG. 4C shows that, following addition of doxycycline, cells positive for iRFP and 20nt gRNA expression are detectable around 24h after transfection and remain high in iRFP expression until 96h. Shown are percent of cells expressing EBFP>107 MEFL and iRFP>106 5 relative to uninduced population. Each set of bars, left to right: 24h, 48h, 72h, 96h. FIG. 4D shows the fraction of cells that have EYFP above autofluorescence relative to uninduced population in different treatment conditions and overtime. Shown are percent of cells expressing EBFP>10 MEFL and EYFP>105 5 relative to uninduced population. Each set of bars, left to right: 24h, 48h, 72h, 96h. In FIG. 4E, the bars show the geometric mean ratio and standard deviation of mean ratio of uninduced vs. fully induced samples, for cells expressing > 10 MEFL of transfection marker EBFP. Group 1 includes cells that received doxycycline (4000nM) at the time of transfection and group 2 includes cells that received doxycycline 24h after the transfection. A slower dynamic was observed in group 2, possibly due to initial accumulation of EYFP protein. For all figures, n = 3 independent technical replicates combined from three experiments. Each set of bars, left to right: 48h, 96h.
FIGs. 5A-5B provide insight into the design rules based on the concentrations of Cas9-VPR, 14nt gRNA, and 20nt gRNAs. FIG. 5A is a schematic of a genetic kill switch designed such that 20nt and 14nt gRNAs compete for the same target site within a CAP. FIG. 5B shows varying the dosages of transfected plasmids encoding Cas9-VPR, 14nt gRNA, 20nt-gRNA between low (5ng), medium (25ng for 14nt gRNA and 50ng for 20nt gRNA) and high (250ng) helps unravel some design rules. Each line represents a single condition of transfection with corresponding Cas9, 14nt gRNA, and 20nt gRNA plasmid levels in front of the fold change observed upon addition of doxycycline. Bar graphs show fold change of geometric mean and s.d. of means of EYFP over uninduced cells for cells expressing >3xl0 MEFL transfection marker EBFP. n = 3 independent technical replicates combined from three experiments. FIGs. 6A-6B show the design and analysis of a genetic kill switch that functions based on DNA cleavage in the Cas9-VPR coding sequence. FIG. 6A is a schematic of a genetic kill switch designed such that the presence of 20nt gRNAs leads to Cas9-VPR- mediated cleavage within its own coding sequence and thereby reverses the output EYFP and tdTomato levels. Comparing cells that either received 20nt gRNAs or did not, there is nearly a 5 fold de-repression of EYFP and about 1.4 fold decrease in tdTomato expression. Shown are geometric mean and s.d. of means of EYFP and tdTomato for cells expressing >10 MEFL transfection marker EBFP. n = 4 independent technical replicates combined from three experiments.
FIGs. 7A-7B show the design and analysis of a genetic kill switch that operates based on DNA cleavage in TALER coding sequence and reversal of a transcriptional repression device. FIG. 7A shows schematics of the kill switch involving a TALER-based
transcriptional repression unit and Cas9-VPR mediated DNA mutation within TALER DNA sequence. FIG. 7B shows the geometric mean and s.d. of means of EYFP for cells expressing >10 MEFL of transfection marker EBFP (n=3 technical replicates). Tl-4 refer to 20nt gRNAs that cut at different regions in TALER coding sequence.
FIGs. 8A-8B show layering of the kill switch and cascade of the Cas9-VPR-mediated transcriptional repression devices. FIG. 8A is a schematic of the layered kill switch. FIG. 8B shows the geometric mean and s.d. of means of EYFP for cells expressing >10 MEFL of transfection marker EBFP. Output is compared between cells with or without gRNA- encoding plasmids that cut within TALER coding sequences, (n = 3 technical replicates).
DETAILED DESCRIPTION CRISPR technology has been widely applied for genome editing and modulation. The ease of engineering of the gRNA of the CRISPR system makes it an attractive platform for generating synthetic gene circuits and for synthetic biology purposes. A multifunctional CRISPR system has been applied here to engineer genetic circuits (simple and multi-layer) that can be used for generating safety off and kill switches with lesser genetic materials than available in the prior art. Thus, the technology of the invention involves the generation of circuits that can be packaged into delivery vehicles such as viruses that contain load limit for therapeutics, in a manner that could not be achieved using prior art methods. With the development of gene and cell-based therapies that have revolutionized cancer therapy and other hard to treat diseases, there is an increasing need to develop and deliver additional regulatory mechanisms to control for specificity of these biological treatments or minimize off target effects. The synthetic biology-based genetic circuits of the invention provide significant advantages that allow for custom designs that are capable of incorporating multiple inputs/signals from environments and cells, leading to the generation of a desired outcome (intended by current gene or cell-based therapies, referred to herein as nucleic acid based therapeutic agents) after and only after receiving and processing those inputs/signals. Complex gene circuits have great utility because they allow better specificity and tighter controls for the desired therapeutic purposes such as safety switches. However, the more complex gene circuits become, the harder they become to engineer because of the metabolic load they create on cells. A single Cas9 protein with multiple functionality (cleaving and transcriptional activation/ repression), such as that claimed herein, has great advantages because it provides better flexibility to engineer complex and multilayer genetic switches. These functionalities are achieved simply by altering and engineering gRNAs (which are small and easier to engineer).
Multi-layered and complex genetic off and kill switches in human cells using a Cas9 nuclease fused to a transcriptional activation domain (VPR), referred to as a multifunctional CRISPR was developed, as described in the examples below. A multi-layer and complex genetic kill switch, which is unique in human cells, can now be achieved using the technology of the invention. Truncating gRNA from the 5' end decreases nuclease activity of Cas9-VPR complex while retaining its DNA binding capacity. Consequently, several genetic kill switches (and off switches) with increasing complexity were developed using shared and single Cas9-VPR and multiple gRNAs of different lengths. The complexity of the circuits achieved, the ease of engineering a lesser DNA footprint (a shared Cas9-VPR with multiple functions), and the use in therapeutic applications (safety switches) are highlights of the present invention.
A Cas nuclease is part of a CRISPR system. The components of the synthetic regulatory system of the invention may be in the form of one or more polynucleotide sequences. For instance, one or more polynucleotides may have sequences which encode a Cas nuclease, the at least 2 gRNAs (guide RNAs) and optionally a tracr sequence. When transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence- specific binding of a CRISPR complex to the target sequence. The polynucleotide sequence may be DNA or RNA or hybrids thereof.
A CRISPR enzyme is typically a type I or III CRISPR enzyme, preferably a type II CRISPR enzyme. The type II CRISPR enzyme may be any Cas enzyme. A preferred Cas enzyme is a Cas9 enzyme. The Cas9 enzyme may be from a spCas9 or saCas9 or may have a high degree of sequence homology with, a wildtype enzyme. The Cas enzyme can be any naturally-occurring Cas9 as well as any chimaeras, mutants, homologs or orthologs.
The polynucleotides may be under the control of a promoter, such as an inducible promoter. Inducible promoters allow regulation of gene expression and can be regulated by exogenously supplied compounds, environmental factors such as temperature, or the presence of a specific physiological state, e.g., acute phase, a particular differentiation state of the cell, or in replicating cells only. Inducible promoters and inducible systems are available from a variety of commercial sources, including, without limitation, Invitrogen, Clontech and Ariad. Many other systems have been described and can be readily selected by one of skill in the art. Examples of inducible promoters regulated by exogenously supplied promoters include the zinc-inducible sheep metallothionine (MT) promoter, the dexamethasone (Dex) -inducible mouse mammary tumor virus (MMTV) promoter, the T7 polymerase promoter system [WO 98/10088]; the ecdysone insect promoter [No et al, Proc. Natl. Acad. Sci. USA, 93:3346- 3351 (1996)], the tetracycline-repressible system [Gossen et al, Proc. Natl. Acad. Sci. USA, 89:5547-5551 (1992)], the tetracycline-inducible system [Gossen et al, Science, 268: 1766- 1769 (1995), see also Harvey et al, Curr. Opin. Chem. Biol., 2:512-518 (1998)], the RU486- inducible system [Wang et al, Nat. Biotech., 15:239-243 (1997) and Wang et al, Gene Ther., 4:432-441 (1997)] and the rapamycin-inducible system [Magari et al, J. Clin. Invest., 100:2865-2872 (1997)]. Still other types of inducible promoters which may be useful in this context are those which are regulated by a specific physiological state, e.g., temperature, acute phase, a particular differentiation state of the cell, or in replicating cells only.
The system of the invention may be used as a safety switch. For instance it may be used to control the expression and activity of intracellular nucleic acid target DNA in highly regulatable and precise manner. The target nucleic acid may be a nucleic acid or cellular therapy. The system of the invention can be designed to target DNA sequences of these therapeutics in order to reverse or shut down the effects of such therapeutics. In some instances the target DNA may be disrupted in its entirety in response to the methods of the invention. In some instances at least about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% of the target DNA is disrupted by use of the systems described herein. In some embodiments, at least about 60%, 70%, or 80% by of the target DNA is disrupted by administration of the systems of the invention. In some embodiments, at least about 85%, 90%, or 95% or more of the target DNA is disrupted.
The systems are useful for disrupting or interfering with the activity of therapeutics such as gene therapy, plasmid or viral vectors, cell based therapies such as CAR-Ts. Using the systems of the invention each of these therapies may be selectively turned off, for instance when the therapy is complete or if the subject has an adverse reaction to the therapy. Other uses are evident to the skilled artisan.
The phraseology and terminology used herein is for the purpose of description and should not be regarded as limiting. The use of "including," "comprising," "having,"
"containing," "involving," and variations thereof, is meant to encompass the items listed thereafter and additional items. Use of ordinal terms such as "first," "second," "third," etc., in the claims to modify a claim element does not by itself connote any priority, precedence, or order of one claim element over another or the temporal order in which acts of a method are performed. Ordinal terms are used merely as labels to distinguish one claim element having a certain name from another element having a same name (but for use of the ordinal term), to distinguish the claim elements.
The present invention is further illustrated by the following Examples, which in no way should be construed as further limiting. The entire contents of all of the references (including literature references, issued patents, published patent applications, and co-pending patent applications) cited throughout this application are hereby expressly incorporated herein by reference.
EXAMPLES
Example 1: Cas9 gRNA engineering for selectable genome editing, activation, and repression
To date, no method exists that allows switching between Cas9 nuclease-dependent and -independent functions with relative ease. The ability for a single Cas9 protein to simultaneously perform genomic modifications while also modulating transcription would allow a user to gain control over two of the critical biomolecules in the cell, DNA and RNA. Such a tool would be transformative for a variety of applications, including therapeutic interventions, genetic screening, and synthetic genetic circuits1"4.
In its native form, Cas9 is directed to a specific DNA sequence by a short guide RNA (gRNA) that contains 20 nucleotides (nt) complementary to its target. Truncated gRNAs, with 17 nt complementarity), have been shown to decrease undesired mutagenesis at some off-target sites without sacrificing on-target genome editing efficiencies5. In the same study, however, gRNAs containing <16nt showed a drastic reduction in nuclease activity.
Analogous to earlier experiments examining the effects of increasing numbers of mismatches within the gRNA6, it was thought that the lack of DNA cleavage in the 16nt gRNA case is not due to a lack of DNA binding, but instead caused by inability of Cas9 to cleave the target substrate post-binding.
A number of synthetic transcriptional devices and layered circuits in human cells were generated using the multifunctional CRISPR system to test the feasibility of such system for synthetic biology purposes. A library of previously described CRISPR-repressible promoters (CRPs)9 was first developed in order to identify promoter architectures that allow efficient Cas9-VPR mediated transcriptional repression (FIGs. 2A, 3). A parallel experiment was then performed using the high-performance member of this promoter library (CRP-8, referred to as CRP-a in subsequent experiments) and similar repression efficiency (~ 10-fold) was confirmed using dCas9 or Cas9-VPR with a 14nt gRNA to this promoter (FIG. 1A).
The use of Cas9-VPR and 14nt gRNAs in a single cell to achieve simultaneous transcriptional activation and repression was then evaluated. A CRP was placed upstream of Enhanced Yellow Protein (EYFP) and a CRISPR-activatable promoter (CAP) was placed upstream of tdTomato fluorescent protein, and were transfected into HEK293FT cells with other circuit regulatory elements. Flow cytometry analysis 48h post transfection showed simultaneous repression and activation of fluorescent reporters (~15-fold) were achieved with two 14nt gRNAs that target Cas9-VPR to the two promoters (FIGs. IB, 2B).
Subsequently, a genetic kill switch in which a 20nt gRNA that cuts within a CAP, is expressed under a tetracycline response element (TRE) promoter was designed9'10. In the absence of a small molecule inducer (doxycycline), Cas9-VPR in combination with constitutively expressed 14nt gRNA for the same target within the CAP activates expression of EYFP. Upon addition of doxycycline, the 20nt guide enables Cas9-VPR to bind and cut within the CAP, leading to reduction of EYFP expression (FIGs. 1C, 2C). When a similar circuit was employed where Cas9-VPR was replaced with nuclease-null dCas9-VPR, doxycycline addition led to an increase rather than reduction of EYFP expression (FIG. 1C). Further analysis of this circuit revealed the dynamics and dosage response within this circuit topology (FIGs. 4-5).
A genetic kill switch design that operates by modulating the availability of Cas9-VPR within a cell was then tested. In the circuit, in the presence of a pair of full length 20nt gRNAs targeting the middle of the Cas9-VPR coding sequence, the guides directed Cas9- VPR to cut and disable itself and by doing so, decreased the available pool of Cas9-VPR within the cell, ultimately causing reduction of Cas9-VPR andl4nt gRNAs mediated inhibition or activation of the two fluorescent reporters (FIG. 14).
Next, progressively complex genetic kill switches that ultimately incorporate the three discussed functions of a single Cas9-VPR protein were designed and analyzed. To this end, one of the previously characterized Transcription Activator-Like Effector repressors
(TALER) 11 ' 12 was employed, and whether Cas9-VPR could cleave within the TALER coding sequence and decrease available TALER, thus removing its repression of EYFP was examined (FIG. 7). A modified U6 promoter9 regulated by TALER was generated, which enabled one to connect the above genetic kill switch with a Cas9-VPR 14nt gRNA repression device. Transfection of this circuit in HEK293FT cells exhibited repression of output EYFP upon addition of input 20nt gRNAs that cut within the TALER coding sequence (FIG. 8). Finally, the genetic kill switch described in FIG. 8 was combined and interconnected with a Cas9-VPR-mediated transcriptional activation device to build a multilayered genetic circuit that simultaneously incorporates CRISPR-mediated transcriptional repression, activation, and DNA cleavage in a single circuit to modulate the output (FIGs. ID, 2D). Flow cytometry analysis 24 and 48 h after transfection of HEK293FT revealed a functional circuit regulated by the input 20nt gRNA against TALER (FIG. ID).
The ability of a single Cas9 protein to regulate RNA production while also maintaining the capacity to cleave DNA will be of great use in deciphering complex biological interactions and developing artificial genetic circuits. A promising use of the gRNA design principles will be in easily extending existing Cas9-based genome editing systems to concurrently modulate gene expression. This is particularly appealing in cases where considerable effort has been expended towards generating Cas9-expressing strains of mice or other labor-intensive and costly model systems13'14. Further, the data suggests that nuclease-positive Cas9 can be easily endowed with other previously described dCas9 activities15'16 such as in vivo chromosomal tracking17 and facilitates the development of multifunctional synthetic genetic safety circuits with potential biomedical applications. Materials and Methods
Fluorescent Reporter Assay for Quantifying Cas9 Activation
Fluorescent reporter experiments for FIGs. 3-4 were conducted with a plasmid (Addgene #47320) modified to include an extra gRNA binding site lOObp upstream of the already existing one. For ST1 and SA Cas9 experiments the protospacer remained the same but the PAM sequence was modified as needed for ST1 or SA Cas9. For FIG. 6, all experiments were conducted with a reporter with a single gRNA binding site. Reporter 1 denotes Addgene #47320, reporters 2 and 3 are similar to reporter 1 except the protospacer and PAM (in bold) were changed to contain the sequence
GGGGCCACTAGGGACAGGATTGG (SEQ ID NO: 1) and
AAGAGAGACAGTACATGCCCTGG (SEQ ID NO: 2) respectively. gRNAs of various length were co-transfected along with the indicated Cas9 protein and reporter into HEK293T cells along with an EBFP2 transfection control. Cells were analyzed by flow cytometry 48 hours post transfection and then when necessary were lysed to extract genomic DNA. Reporter Deletion Analysis
DNA was extracted using QuickExtract DNA Extraction Solution (Epicentre). DNA was then used for PCR to amplify desired regions. The amplified samples were then run on a 2% agarose gel stained with GelGreen (Biotium) and visualized using Gel Doc EZ (Bio-Rad). Band intensity was quantified using GelAnalyzer. qRT-PCR Analysis
Samples were lysed and RNA was extracted using the RNeasy Plus Mini Kit
(Qiagen). cDNA was made using the iScript cDNA synthesis kit (Bio-Rad) with 500ng of RNA. KAPA SYBR FAST Universal 2X qPCR Master Mix (Kapa Biosystems) was used for qPCR with 0.5 μΐ of cDNA used for each reaction. Activation was analyzed using CFX96 Real-Time PCR Detection System (Bio-Rad). Gene expression levels were normalized to β- actin levels. Endogenous Indel Analysis
DNA was extracted from 24-well plates using 350 μΐ of QuickExtract DNA
Extraction Solution (Epicentre), according to the manufacturing instructions. Amplicon library preparation was performed using two PCRs. The first PCR to amplify from the genome, add appropriate barcodes and parts of adapters for Illumina sequencing. The second PCR extended out the Illumina adapters. In the first PCR, 5 μΐ^ of extracted DNA was used as template in a 100 μΐ^ Kapa HiFi PCR reaction and run for 30 cycles. PCR products were then purified using a homemade SPRI bead mixture and eluted in 50 μΐ^ of elution buffer. For the second PCR, 2 μL· of the previous first round PCR was used as template in a 25 μΐ^ reaction and PCRs were run for a total of 9 cycles. PCR products were then run on an agarose gel, extracted and column purified. Equal amounts of each sample were then pooled and sequenced on an Illumina MiSeq using the paired end 150 MiSeq Nano kit.
Mate pair reads were merged into single contigs using FLASH 18. Each contig was then mapped to a custom reference representing the three amplicons using bwa mem19. SAM output files were then converted to BAM files and pileup files were generated for each sample using SAM tools 20. Pileup files were then analyzed using custom python scripts to determine observed mutation rates. Mutations were only counted if the mutations spanned some portion of the sgRNA target site. In addition, base quality scores of > 28 were also required for any mutations to be called. To minimize the impact of sequencing error, single base substitutions were excluded in this analysis.
RNA Sequencing for Quantifying Activator Specificity
For each sample, 200 ng of total RNA was polyA selected using Dynabeads mRNA Purification Kit (Life Technologies). The RNA was then DNAse treated with Turbo DNase (Life Technologies) and cleaned up with Agencourt RNAClean XP Beads (Beckman
Coulter). RNA-Seq Libraries were made using the NEBNext Ultra RNA Library Prep Kit for Illumina (New England BioLabs) according to the manufacturer's instructions with NEBNext Multiplex Oligos (New England BioLabs). Libraries were analyzed on a BioAnalyzer using a High Sensitivity DNA Analysis Kit (Agilent). Libraries were then quantified using a
KAPA Library Quantification Kit (KAPA Biosystems) and pooled to a final concentration of 4 nM. Sequencing was performed on an Illumina NextSeq instrument with paired end reads. Reads were aligned to the hgl9 UCSC Known Genes annotations using RSEM v 1.2.1 and analyzed in Python and R. Differential gene expression analysis was done using the Voom 22 and Limma 23 packages in R for all genes with > 1 TPM in each replicate, and a one-way within-subjects ANOVA was performed on the number of differentially expressed genes for each condition to quantify off-target effects, where differential expression was defined by Benjamini-Hochberg adjusted /?-value < 0.05 and fold-change > 2 or < 0.5. Raw RNA-seq data available at NCBI's Geo database: Accession number GSE70694.
Statistical Analysis
All T-tests performed via GraphPad QuickCalcs Web Site
graphpad.com/quickcalcs/ttestl/?Format=SEM (accessed June 2015.
Cell Culture for Endogenous Target Mutation/Activation or Deletion Reporter
HEK-293T cells were cultivated in Dulbecco's Modified Eagle Medium (Life Technologies) with 10% FBS (Life Technologies) and Penicillin/Streptomycin (Life
Technologies). Incubator conditions were 37 °C and 5% C02. Cells were tested for mycoplasma yearly. Cells were seeded into 24-well plates at 50,000 cells per well and transfected with 200ng of Cas9 construct, lOng of guide, 60ng of reporter (for reporter experiments), 25ng of EBFP2 (for reporter experiments) via Lipofectamine 2000 (Life Technologies). Post transfection, cells were grown for 48-72 hours and lysed for either RNA or DNA extraction.
Cell Culture for Circuit Experiments
Experiments were carried out in HEK293FT cells that were obtained from ATCC or were a gift from P. Mali , maintained in DMEM (CellGro) supplemented with 10% FBS (PAA Laboratories), 1% 1-glutamine-streptomycin- penicillin mix (CellGro) and 1% nonessential amino acids (NEAA; HyClone) at 37 °C and 5% C02 and tested for mycoplasma contamination. Transfections were performed using lipofectamine LTX and Attractene reagents (QIAGEN). Cells were seeded the day before transfection at 2 x 105 cells per well in a 24-well plate. In control experiments, the DNA plasmid under study was replaced with an equivalent amount of empty DNA plasmid to maintain the total amount of transfected DNA constant among the groups. For transfections involving Attractene reagent, cocktails of plasmid DNAs were mixed and added to serum free DMEM to a total volume of 70μ1. 1.5- 2μ1 of Attractene was then added to each tube of DNA/DMEM mixtures, and the tube was gently mixed and kept at room temperature for 25 min to form the DNA-liposome complex. For experiments involving Lipofectamine LTX, cocktails of plasmid DNAs, serum- free DMEM and the Plus Reagent were mixed and incubated for lOmin. In parallel, LTX reagent was mixed with the serum-free media and incubated for the same period of time. After 10 min, the two reagents were mixed and incubated for an additional 30 min. Fresh medium was added to the cells directly before transfection (500 ml of DMEM with supplements). The DNA-reagent solution was then added drop- wise to the wells. Induction of the circuit was performed at this time as well by addition of doxycycline.
Vector Design and Construction
Reporter gRNA was previously described (Addgene #48672), dCas9-VPR was previously described (Addgene #63798) and Cas9 was described (Addgene# 41815). Cas9- VPR was cloned via Gateway assembly (Invitrogen) based on the Cas9 plasmid. gRNAs for endogenous targets were cloned into Addgene #41817 and transiently transfected. Plasmids used for synthetic circuits were constructed using the Gateway system. The U6-driven gRNA expression cassettes were ordered as blocks from IDT and cloned into a plasmid backbone using Golden Gate cloning. The library of CRPs were ordered as gene fragments from IDT and assembled into an appropriate promoter entry vector. Cas9-VPR Plasmids used in this study will be made available on Addgene (Addgene # 68495,68496,68497,68498).
Flow Cytometry for Circuit Experiments
Flow cytometry data were collected 48 h after transfection. Cells were trypsinized and centrifuged at 453g for 5 min at 4 °C. The supernatant was then removed, and the cells were resuspended in Hank's balanced salt solution without calcium or magnesium supplemented with 2.5% FBS. BD LSRII was used to obtain flow cytometry measurements with the following settings: EBFP, measured with a 405 nm laser and a 450/50 filter; EYFP, measured with a 488 nm laser and a 530/30 filter; tdTomato, measured with a 561 nm laser and a 695/40 filter. Non-transfected controls were included in each experiment. Data shown in the figures are geometric mean and s.d. of means for cells expressing the transfection marker EBFP. Sample sizes were predetermined for each experiment based on initial pilot experiments. At least 100,000 flow cytometry events were gathered per biological replicate. Statistical Analysis for Circuit Experiments
Flow cytometry data were converted from arbitrary units to compensated molecules of equivalent fluorescein (MEFL) 24 using the Tool-Chain to Accelerate Synthetic Biological Engineering (TASBE) characterization25(MIT CSAIL Tech. Report 2012-008 (2012). An affine compensation matrix is computed from single positive and blank controls. FITC measurements are calibrated to MEFL using SpheroTech RCP-30-5-A beads, and mappings from other channels to equivalent FITC are computed from co-transfection of constitutive blue, yellow and red fluorescent proteins, each controlled by the CAG promoter on its own otherwise identical plasmid. Non-transfected controls were included in each experiment. Sample sizes were pre-determined for each experiment. Data shown in the figures are geometric mean and s.d. of means for cells expressing the transfection marker enhanced blue fluorescent protein (EBFP) based on the MEFL threshold set. More precisely, a threshold as a cutoff for each data set was selected based on the observed constitutive fluorescence distributions, and data below that threshold was excluded as being too close to the non- transfected population. Then the MEFL data was divided by constitutive fluorescent protein expression into logarithmic bins at 10 bins per decade, and the geometric mean and variance for those data points in each bin were calculated. High outliers were removed by excluding bins without at least 100 data points. In fact, both population and per-bin geometric statistics were calculated using this filtered set of data. Exclusion criteria for samples during flow cytometry analysis are the following predetermined criteria: samples containing less than 10% of the number of events or less than 10% of the fraction of successful transfections of the mode for the batch in which they were collected. Reproducibility
Sample sizes for each experiment were chosen based on an initial pilot experiment and were further guided by sample sizes from similar experiments and publications. No randomization or blinding was used in the course of the experiments. No data were excluded from analysis. REFERENCES
1. Hsu, P. D., E. S. Lander, and F. Zhang, Cell 157 (6), 1262-1278 (2014).
2. Sander, J. D. and J. K. Joung, Nature biotechnology 32 (4), 347-355 (2014).
3. Qi, L. S. et al., Ce// 152 (5), 1173-1183 (2013).
4. Mali, P., K. M. Esvelt, and G. M. Church, Nature methods 10 (10), 957-963 (2013).
5. Fu, Y., J. D. Sander, D. Reyon, V. M. Cascio, and J. K. Joung, Nature biotechnology
32 (3), 279-284 (2014).
6. Jiang, W., D. Bikard, D. Cox, F. Zhang, and L. A. Marraffini, Nature biotechnology
31 (3), 233-239 (2013).
7. Chavez, A. et al., Nature methods 12 (4), 326-328 (2015).
8. Esvelt, K. M. et al., Nature methods 10 (11), 1116-1121 (2013).
9. Kiani, S. et al., Nature methods 11 (7), 723-726 (2014).
10. Nissim, L., S. D. Perli, A. Fridkin, P. Perez-Pinera, and T. K. Lu, Molecular cell 54 (4), 698-710 (2014).
11. Li, Y. et al., Nature chemical biology 11 (3), 207-213 (2015).
12. Davidsohn, N. et al., ACS synthetic biology 4 (6), 673-681 (2015).
13. Dow, L. E. et al., Nature biotechnology 33 (4), 390-394 (2015).
14. Piatt, R. J. et al., Cell 159 (2), 440-455 (2014).
15. Perez-Pinera, P. et al., Nature methods 10 (10), 973-976 (2013).
16. Maeder, M. L. et al., Nature methods 10 (10), 977-979 (2013).
17. Chen, B. et al., Cell 155 (7), 1479-1491 (2013).
18. Magoc, T. and S. L. Salzberg, Bioinformatics 27 (21), 2957-2963 (2011).
19. Li, H. and R. Durbin, Bioinformatics 25 (14), 1754-1760 (2009).
20. Li, H. et al., Bioinformatics 25 (16), 2078-2079 (2009).
21. Li, B. and C. N. Dewey, BMC bioinformatics 12, 323 (2011).
22. Law, C. W., Y. Chen, W. Shi, and G. K. Smyth, Genome biology 15 (2), R29 (2014).
23. Smyth, G. K., Statistical applications in genetics and molecular biology 3, Article3 (2004).
24. Hoffman, R. A., L. Wang, M. Bigos, and J. P. Nolan, Cytometry. Part A : the journal of the International Society for Analytical Cytology 81 (9), 785-796 (2012).
25. Beal, J., Frontiers in bioengineering and biotechnology 2, 87 (2014). EQUIVALENTS
Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.
All references, including patent documents, disclosed herein are incorporated by reference in their entirety.

Claims

CLAIMS What is claimed is:
1. A synthetic regulatory system comprising a multifunctional Cas nuclease and at least two distinct gRNAs, wherein the synthetic regulatory system modulates cleavage and transcription in a mammalian cell.
2. The synthetic regulatory system of claim 1, wherein the system is a safety switch.
3. The synthetic regulatory system of claim 1 or 2, wherein the two distinct gRNAs comprise a first gRNA of less than 15 nucleotides in length and a second gRNA of 15 or greater nucleotides in length.
4. The synthetic regulatory system of claim 3 wherein the first gRNA has a length of 10- 14 nucleotides.
5. The synthetic regulatory system of claim 3, wherein the second gRNA has a length of 16-20 nucleotides.
6. The synthetic regulatory system of any one of claims 1-5, wherein a nucleic acid encodes the Cas nuclease and the at least two distinct gRNAs.
7. The synthetic regulatory system of any one of claims 1-5, wherein the Cas nuclease is fused to a transcriptional activation domain.
8. The synthetic regulatory system of claim 7, wherein the transcriptional activation domain is VPR.
9. The synthetic regulatory system of any one of claims 1-5, wherein the synthetic regulatory system modulates cleavage and transcriptional activation.
10. The synthetic regulatory system of any one of claims 1-5, wherein the synthetic regulatory system modulates cleavage and transcriptional repression.
11. The synthetic regulatory system of any one of claims 1-5, wherein the synthetic regulatory system modulates cleavage, transcriptional repression and transcriptional activation.
12. A method for regulating a nucleic acid based therapeutic agent, comprising
contacting a cell having a nucleic acid based therapeutic agent with a synthetic regulatory system comprising a multifunctional Cas nuclease and at least two distinct gRNAs, wherein the synthetic regulatory system modulates cleavage and transcription of the nucleic acid based therapeutic agent in the cell.
13. The method of claim 12, wherein the nucleic acid based therapeutic agent is a DNA based vaccine.
14. The method of claim 12, wherein the nucleic acid based therapeutic agent is a gene therapy.
15. The method of claim 12, wherein the nucleic acid based therapeutic agent is a chimeric antigen receptor T cell (CAR-T).
16. The method of any one of claims 12-15, wherein the synthetic regulatory system modulates cleavage and transcription of the nucleic acid based therapeutic agent in the cell when exposed to an exogenous factor.
17. The method of any one of claims 12-15, wherein the synthetic regulatory system modulates cleavage and transcription of the nucleic acid based therapeutic agent in the cell when exposed to a cellular factor.
PCT/US2016/049907 2015-09-04 2016-09-01 Multilayer genetic safety kill circuits based on single cas9 protein and multiple engineered grna in mammalian cells WO2017040786A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/755,623 US20180251789A1 (en) 2015-09-04 2016-09-01 Multilayer genetic safety kill circuits based on single cas9 protein and multiple engineered grna in mammalian cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562214839P 2015-09-04 2015-09-04
US62/214,839 2015-09-04

Publications (1)

Publication Number Publication Date
WO2017040786A1 true WO2017040786A1 (en) 2017-03-09

Family

ID=58188538

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/049907 WO2017040786A1 (en) 2015-09-04 2016-09-01 Multilayer genetic safety kill circuits based on single cas9 protein and multiple engineered grna in mammalian cells

Country Status (2)

Country Link
US (1) US20180251789A1 (en)
WO (1) WO2017040786A1 (en)

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9999671B2 (en) 2013-09-06 2018-06-19 President And Fellows Of Harvard College Delivery of negatively charged proteins using cationic lipids
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
US10113163B2 (en) 2016-08-03 2018-10-30 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
US10167457B2 (en) 2015-10-23 2019-01-01 President And Fellows Of Harvard College Nucleobase editors and uses thereof
WO2019005851A1 (en) * 2017-06-26 2019-01-03 Arizona Board Of Regents On Behalf Of Arizona State University A universal platform to enhance crispr-based gene editing for in vivo therapies
WO2019005856A1 (en) * 2017-06-26 2019-01-03 Arizona Board Of Regents On Behalf Of Arizona State University Crispr logic circuits for safer and controllable gene therapies
WO2019005853A3 (en) * 2017-06-26 2019-05-02 Arizona Board Of Regents On Behalf Of Arizona State University Crispr-based synthetic gene circuits as next generation gene therapy of inner ear
US10323236B2 (en) 2011-07-22 2019-06-18 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US10465176B2 (en) 2013-12-12 2019-11-05 President And Fellows Of Harvard College Cas variants for gene editing
US10508298B2 (en) 2013-08-09 2019-12-17 President And Fellows Of Harvard College Methods for identifying a target site of a CAS9 nuclease
US10597679B2 (en) 2013-09-06 2020-03-24 President And Fellows Of Harvard College Switchable Cas9 nucleases and uses thereof
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
US10858639B2 (en) 2013-09-06 2020-12-08 President And Fellows Of Harvard College CAS9 variants and uses thereof
US11046948B2 (en) 2013-08-22 2021-06-29 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US11268082B2 (en) 2017-03-23 2022-03-08 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable DNA binding proteins
US11306324B2 (en) 2016-10-14 2022-04-19 President And Fellows Of Harvard College AAV delivery of nucleobase editors
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
WO2022162247A1 (en) * 2021-02-01 2022-08-04 Epsilen Bio S.R.L. Gene silencing
US11447770B1 (en) 2019-03-19 2022-09-20 The Broad Institute, Inc. Methods and compositions for prime editing nucleotide sequences
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
US11795443B2 (en) 2017-10-16 2023-10-24 The Broad Institute, Inc. Uses of adenosine base editors
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
US11912985B2 (en) 2020-05-08 2024-02-27 The Broad Institute, Inc. Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
US11932884B2 (en) 2022-03-21 2024-03-19 President And Fellows Of Harvard College High efficiency base editors comprising Gam

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140356958A1 (en) * 2012-12-17 2014-12-04 President And Fellows Of Harvard College RNA-Guided Human Genome Engineering

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140356958A1 (en) * 2012-12-17 2014-12-04 President And Fellows Of Harvard College RNA-Guided Human Genome Engineering

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHAVEZ ET AL.: "Highly-efficient Cas9-mediated transcriptional programming", NAT METHODS., vol. 12, no. 4, April 2015 (2015-04-01), pages 326 - 328, XP055371318 *
ESVELT ET AL.: "Orthogonal Cas9 Proteins for RNA-Guided Gene Regulation and Editing.", NAT METHODS., vol. 10, no. 11, 2013, pages 1116 - 1121, XP055128928 *
JINEK ET AL.: "A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity.", SCIENCE, vol. 337, no. 6096, 2012, pages 816 - 821, XP055067740 *
KIANI ET AL.: "Cas9 gRNA engineering for genome editing, activation and repression.", NAT METHODS., vol. 12, no. 11, November 2015 (2015-11-01), pages 1051 - 1054, XP055254915 *
SAKUMA ET AL.: "Multiplex genome engineering in human cells using all-in-one CRISPR/Cas9 vector system.", SCI REP., vol. 4, 2014, pages 1 - 6, XP055196391 *

Cited By (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10323236B2 (en) 2011-07-22 2019-06-18 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US10954548B2 (en) 2013-08-09 2021-03-23 President And Fellows Of Harvard College Nuclease profiling system
US10508298B2 (en) 2013-08-09 2019-12-17 President And Fellows Of Harvard College Methods for identifying a target site of a CAS9 nuclease
US11920181B2 (en) 2013-08-09 2024-03-05 President And Fellows Of Harvard College Nuclease profiling system
US11046948B2 (en) 2013-08-22 2021-06-29 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US10912833B2 (en) 2013-09-06 2021-02-09 President And Fellows Of Harvard College Delivery of negatively charged proteins using cationic lipids
US10858639B2 (en) 2013-09-06 2020-12-08 President And Fellows Of Harvard College CAS9 variants and uses thereof
US11299755B2 (en) 2013-09-06 2022-04-12 President And Fellows Of Harvard College Switchable CAS9 nucleases and uses thereof
US9999671B2 (en) 2013-09-06 2018-06-19 President And Fellows Of Harvard College Delivery of negatively charged proteins using cationic lipids
US10682410B2 (en) 2013-09-06 2020-06-16 President And Fellows Of Harvard College Delivery system for functional nucleases
US10597679B2 (en) 2013-09-06 2020-03-24 President And Fellows Of Harvard College Switchable Cas9 nucleases and uses thereof
US10465176B2 (en) 2013-12-12 2019-11-05 President And Fellows Of Harvard College Cas variants for gene editing
US11053481B2 (en) 2013-12-12 2021-07-06 President And Fellows Of Harvard College Fusions of Cas9 domains and nucleic acid-editing domains
US11124782B2 (en) 2013-12-12 2021-09-21 President And Fellows Of Harvard College Cas variants for gene editing
US10704062B2 (en) 2014-07-30 2020-07-07 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
US11578343B2 (en) 2014-07-30 2023-02-14 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
US10167457B2 (en) 2015-10-23 2019-01-01 President And Fellows Of Harvard College Nucleobase editors and uses thereof
US11214780B2 (en) 2015-10-23 2022-01-04 President And Fellows Of Harvard College Nucleobase editors and uses thereof
US11702651B2 (en) 2016-08-03 2023-07-18 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
US10947530B2 (en) 2016-08-03 2021-03-16 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
US10113163B2 (en) 2016-08-03 2018-10-30 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
US11306324B2 (en) 2016-10-14 2022-04-19 President And Fellows Of Harvard College AAV delivery of nucleobase editors
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
US11820969B2 (en) 2016-12-23 2023-11-21 President And Fellows Of Harvard College Editing of CCR2 receptor gene to protect against HIV infection
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
US11268082B2 (en) 2017-03-23 2022-03-08 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable DNA binding proteins
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
WO2019005853A3 (en) * 2017-06-26 2019-05-02 Arizona Board Of Regents On Behalf Of Arizona State University Crispr-based synthetic gene circuits as next generation gene therapy of inner ear
US11773407B2 (en) 2017-06-26 2023-10-03 Arizona Board Of Regents On Behalf Of Arizona State University CRISPR logic circuits for safer and controllable gene therapies
WO2019005851A1 (en) * 2017-06-26 2019-01-03 Arizona Board Of Regents On Behalf Of Arizona State University A universal platform to enhance crispr-based gene editing for in vivo therapies
WO2019005856A1 (en) * 2017-06-26 2019-01-03 Arizona Board Of Regents On Behalf Of Arizona State University Crispr logic circuits for safer and controllable gene therapies
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
US11795443B2 (en) 2017-10-16 2023-10-24 The Broad Institute, Inc. Uses of adenosine base editors
US11795452B2 (en) 2019-03-19 2023-10-24 The Broad Institute, Inc. Methods and compositions for prime editing nucleotide sequences
US11643652B2 (en) 2019-03-19 2023-05-09 The Broad Institute, Inc. Methods and compositions for prime editing nucleotide sequences
US11447770B1 (en) 2019-03-19 2022-09-20 The Broad Institute, Inc. Methods and compositions for prime editing nucleotide sequences
US11912985B2 (en) 2020-05-08 2024-02-27 The Broad Institute, Inc. Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
GB2617799A (en) * 2021-02-01 2023-10-18 Epsilen Bio S R L Gene silencing
WO2022162247A1 (en) * 2021-02-01 2022-08-04 Epsilen Bio S.R.L. Gene silencing
US11932884B2 (en) 2022-03-21 2024-03-19 President And Fellows Of Harvard College High efficiency base editors comprising Gam

Also Published As

Publication number Publication date
US20180251789A1 (en) 2018-09-06

Similar Documents

Publication Publication Date Title
US20180251789A1 (en) Multilayer genetic safety kill circuits based on single cas9 protein and multiple engineered grna in mammalian cells
Kiani et al. Cas9 gRNA engineering for genome editing, activation and repression
CN112195164B (en) Engineered Cas effector proteins and methods of use thereof
US20220127603A1 (en) Novel crispr rna targeting enzymes and systems and uses thereof
Wang et al. CRISPR/Cas9 in genome editing and beyond
CN112041444A (en) Novel CRISPR DNA targeting enzymes and systems
CA2989834A1 (en) Crispr enzymes and systems
JP2018532419A (en) CRISPR-Cas sgRNA library
KR20220004674A (en) Methods and compositions for editing RNA
JP2018520648A (en) Improved gene editing based on endonuclease in primary cells
CN112823011A (en) Gene targets for T cell-based immunotherapy
CA3106162A1 (en) Methods of achieving high specificity of genome editing
Wang et al. A far-red light–inducible CRISPR-Cas12a platform for remote-controlled genome editing and gene activation
Dominguez et al. CRISPR-mediated synergistic epigenetic and transcriptional control
US11072782B2 (en) Construct for epigenetic modification and its use in the silencing of genes
Chavez et al. Stable expression of large transgenes via the knock-in of an integrase-deficient lentivirus
CN109207518B (en) Drug-inducible CRISPR/Cas9 system for gene transcription activation
Stavrou et al. Episomal vectors based on S/MAR and the β-globin Replicator, encoding a synthetic transcriptional activator, mediate efficient γ-globin activation in haematopoietic cells
Dahiya et al. RAP1 downregulation by miR-320c reduces platelet activation in ex-vivo storage
Porter et al. A polypyrimidine tract-binding protein-dependent pathway of mRNA stability initiates with CpG activation of primary B cells
US20230113805A1 (en) CRISPR-Cas NUCLEASES FROM CPR-ENRICHED METAGENOME
WO2017051000A1 (en) Death receptor based selection marker
CN116601293A (en) Engineered Cas effector proteins and methods of use thereof
Khosraviani et al. Protocol to use RNaseH1-based CRISPR to modulate locus-associated R-loops
Webber et al. Cas9-induced targeted integration of large DNA payloads in primary human T cells via homology-mediated end-joining DNA repair

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16842984

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16842984

Country of ref document: EP

Kind code of ref document: A1